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Summary We have investigated factors influencing the survival of women with early breast cancer in Scotland. In a retrospective study,
clinical, treatment and 'service' factors, e.g. surgical case load, deprivation and geographical area (health board of first treatment) were
recorded from hospital records. A total of 2148 women with invasive breast cancer diagnosed in 1987 were identified from the Scottish
Cancer Registry, of whom 1619 without metastases at diagnosis underwent surgery as part of their primary treatment. In a multivariate
analysis, clinical factors (age, clinical stage, pathological tumoursize, node status and oestrogen receptorstatus) all influenced survival. After
allowing forthese clinical factors, surgical case load and deprivation did not have statistically significant effects on survival. By contrast, health
board did affect survival. This was explalned in part by the selectimn of patients for surgery. There appeared, however, to be a residual effect
that may be related to differences in the use of adjuvant systemic treatment among the different health boards. We conclude that, in Scotland,
geographical variation in both surgical and non-surgical treatment has a greater effect on variability in survival for women with breast cancer
than surgical case load and deprivation.
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Recent studies have raised questions regarding the organization of
care for women with breast cancer and how this affects survival.
Between 1979 and 1988. women in Yorkshire with breast cancer
had significantly better 5-year survival if managed by a surgeon
treating at least 30 cases each year (Sainsbury et al. 1995a). Over a
similar period. treatment by a specialist breast surgeon was associ-
ated with significantly better survi'al in the West of Scotland
(Gillis and Hole. 1996). Socioeconomic deprivation has also been
associated with worse survival. although tumour stage and
pathology did not differ between deprived and affluent women
(Carnon et al. 1994). Finally. in south-east England. survival
appeared to be better for women treated in districts with a teaching
hospital (Basnett et al. 1992).
This study addresses variability in the survival of women in
Scotland identified from cancer registry data who underwent
surgery for breast cancer in 1987. Whereas previous studies have
covered several years. over which practice may have changed
(Carnon et al. 1994: Gillis and Hole. 1996). we focused on a single
year. Importantly. we obtained detailed clinical information from
individual patients' case records rather than registry data alone
(Karjalainen and Pukkala. 1990: Sainsbury et al. 1995a and b:
Schrijvers et al. 1995). Our data are population based rather than
derived from a single institution.
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PATIENTS AND METHODS
Study population
The study was part of a comprehensive survey of patterns of care
in all women with invasive breast cancer recorded by the Scottish
Cancer Registry in 1987 and 1993 (Scottish Breast Cancer Focus
Group. 1996). data that are of high quality in terms of both
accuracy (Brewster et al. 1994) and completeness (Brewster et al.
1997). This study concerns the 1987 cohort. in whom follow-up is
adequate for survival analysis. Except when stated. the analysis
was limited to women with no evidence of distant metastases at
diagnosis. as it is in these women that differences in management
are most likely to influence outcome. In addition. only those
women undergoing surgery as part of their initial management
were included. as data on prognostically important factors do not
exist for women treated non-surgically. Women with a second
primary breast cancer diagnosed in 1987 were identified using
record linkage (Kendrick and Clarke. 1993) and excluded.
Data collection
Permission to examine case notes was obtained from the medical
director of each trust hospital and the chiefadministrative medical
officer of each health board. The health boards. of which there are
15 covering the 5.1 million population in Scotland. represent
districts equivalent to health authorities in the rest of the UK.
Indi'vidual consultants were contacted and all co-operated. The
case notes were examined by Scottish Cancer Therapy Network
(SCTN) data managers.
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Table 1 Unrvanate analysts of survival data: cinical, treatment and seri factors
Perenaep of women Una sed P-u
5-year surviva (%)
(95% C)
Cnolg factors
Age (years)
<50
50-6 65
65-c 80
'80
Clinial stage
Ill
Unknown
Patholocal rnode status
Positive
Negative
Unknown
ER status
Positive
Negative
Unown
Patkoioca tumrnour size
' 2 cm
> 2 cm
Unknown
Servie factors
Health Board
Ayrshire & Arran
Borders
Argyl & Clyde
Fife
Greater Glasgow
Hihland
Islands
Lanarkshire
Graorgan
Lothian
Tayside
Forth Valey
Dumfnrs & Gallway
Depnvation categoy
1 = Least deprived
2 = Irntermediate deprivation
3 = Most deprnved
Surical case bad
One to nine
10-29
> 30 or team
UnknownF
Seen by oncologit
Yes
No
Unknownc
Treatment factors
Type of surgery
Mastectomry
Conserv
Aquvant radotherapy
Given
Not given
A~rvant clhemotherapy
Give
Not given
Ahuvant encnne theapy
Given
Not given
Acuant chemohpy or
endocine therapy
Given
Not grven
30
37
30
4
19
50
12
20
36
37
27
37
24
39
39
41
21
8
1
7
6
21
4
1
8
11
15
9
4
4
25
61
14
17
42
40
1
53
46
2
60
40
41
59
8
92
65
35
70
30
73 (69-77)
74 (70-77)
68 (64-72)
49 (37-60)
84 (80-8)
71 (68-74)
57 (50-64)
66 (61-72)
59 (55-63)
85 (82-87)
68 (64-72)
80 (77-3)
61 (5666)
68 (65-72)
80 (77-3)
62 (59-66)
71 (66-75)
64 (55-72)
68 (49-8)
64 (54-73)
68 (59-78)
74 (69-78)
68 (57-79)
80 (64-96)
67 (60-75)
76 (70-82)
78 (73-84)
66 (59-74)
65 (53-76)
69 (57-81)
74 (70-78)
71 (68-74)
66 (60-72)
67 (61-72)
69 (66-73)
75 (71-78)
Not appicbae
70 (67-74)
72 (68-75)
Not applicable
68 (6-71)
75 (72-79)
70 (67-74)
71 (69-74)
61 (52-70)
72 (69-74)
70 (68-73)
72 (68-75)
028
70 (67-73)
73 (69-77)
The clinical factors examined were pathological tumour size (<
2 cm. > 2 cm). pathological node status (positive. negative).
oestrogen receptor (ER) status (positive > 20 fmol mg-' cytosolic
protein or > 10% staining). patient's age (<50.50-64. 65-79. > 80
years) and clinical stage defined according to TNM criteria based
on standard local staging investigations. Tumour grade was
collected but not included in the analyses as it was not recorded in
52% of biopsies. Treatment factors comprised type of surgery to
the breast (mastectomy. breast conservation). the use of radio-
therapy to the breast. chest wall or axilla. and endocrine treatment
(tamoxifen. ovarian ablation) or chemotherapy as adjuvant
management. Service factors analysed were health board of first
treatment. referral to an oncologist within 3 months of diagnosis.
deprivation and annual breast cancer case load of the surgeon.
Surgeons were classified according to case load (Sainsbury et al.
1995a): these categories were modified to include those surgeons
identified before analysis as working within a breast team in the
group treating at least 30 women a year (1-9. 10-29. > 30 patients
or part of ateam). The Carstairs classification ofsocial deprivation
(Carstairs and Morris. 1991) was used to allocate patients to the
least deprived quintile of the Scottish population (Carstairs cate-
gory 1). the most deprived (category 5) or an intermediate group
(categories 2-4). Follow-up data. including recurrence status at
last follow-up, were collected from case notes. Survival data were
obtained by computerized probabilistic linkage (Kendrick and
Clarke. 1993) to the Registrar General's death records.
Data accuracy was assessed in a review of 100%7 of the 2304
items from a random sample of 18 patients. The error rate was
1.04%. with a 95% confidence interval (CI) of0.63-1.46%.
Data analysis
The primary end point was death from any cause. This was
preferred over cause-specific survival because of the possible
unreliability of cause-of-death information from death certificates
(Maudsley and Williams. 1993). An initial univariate analysis
assessed the effect on outcome ofeach prognostic factor individu-
ally using Kaplan-Meier estimates of survival. Because of
possible confounding effects. such as case mix (e.g. clinical stage.
age. pathological features). a Cox proportional hazards model was
applied to the data. using the forward selection stepwise technique
(Armitage and Berry. 1994). Two models were derived. Both
represented survival adjusted first for significant clinical factors:
the first model also adjusted for significant service factors.
whereas the second model also adjusted for significant treatment
factors. We investigated the validity of the Cox models using log
(minus log) plots and also time-dependent modelling (Collett.
1994) and found the assumption of proportional hazards to be
acceptable.
In the text. point estimates are shown with 95% confidence
intervals. except when otherwise stated. For the multivariate
analysis of survival in relation to clinical. treatment and service
factors. 99% confidence intervals were used to minimize the
effects ofmultiple testing
RESULTS
A total of 2581 women were registered. Of these. 101 were ineli-
gible because of a previous diagnosis of breast cancer. diagnosis
and treatment outside Scotland or non-invasive disease. and 79
because the diagnosis was made only on the death certificate. Of
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Log-rank test for eqtivalence of survival curves. Because of heir smal populations and
geographical skTiantbes. the Orkney. Shetand and Western Isles Health Boards were
analysed as a singxe group, Kienbtfied as the Islands. cThe unknowns were not included in
these analyses
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Table 2 Muivanate analysi of survival data
Acqusd 5-yw per cet swvlva (99% C)
Cudica factors
Age (years)
<50
50-< 65
65-< 80
>80
cIcal stag
76 (74-79)
76 (73-78)
73 (70-76)
58 (54-63)
81 (79-3)
_ .- ,_.
11 74 (71-77)
111 66 (62-69)
Unknown 72 (69-75)
ER status
Positrve 81 (78-3)
Negative 64 (6-68)
Unknown 73 (70-76)
Paftholgcal node status by patol tumour size
Node negative
< 2 cm 89(88-91)
> 2 cm 73(70-76)
Unknown size 85 (83-87)
Node positive
c 2 cm 64 (60-68)
> 2 cm 61 (57-65)
Unknown size 60 (56-64)
Node unknown
c 2 cm 77 (74-0)
> 2 cm 67(63-71)
Unknown size 71 (68-74)
Servic factors
Health Board
Ayrstwre & Arran
Borders
Argyll & Clyde
F e
Greater Glasgow
Highiand
Isands
Lanarkshire
Graropsan
Lothian
Tayside
Forth Valley
Dumnfnes & Galloway
Deprivation category
1 = Least deprived
2 = Intermediate deprivation
3 = Most depnved
Surg case bad
One to
10-29
> 30 or team
Unknownr
Seen by aonlogi
Yes
No
UnknoWn'
Treatment factors
Type of surgery
Mastectomy
Conservation
A Nuvant radot
Given
Not gie
AdWant chemotr
Gmen
Not given
A xuant endcrone thapy
Goen
Not given
A fat chemotherapy or endocine therapy
Goen
Not gOven
67 (6-71)
68 (64-72)
67 (64-71)
66 (63-70)
77 (74-80)
77 (75-80)
84 (82-8)
73 (70-76)
78 (75-80)
79 (77-82)
70 (67-74)
69 (65-72)
74 (71-77)
76 (73-79)
74 (71-77)
71 (68-75)
74 (71-77)
73 (70-76)
75 (72-78)
rno applcble
73 (70-76)
76 (73-79)
not applcable
m- 2.0-
I
P-Ale CD
CD
.2
0.004a >
is
0
-0 1.0.
0.0007a to
N 0.9.
Zs
._ 0.8
*m 0.7.
< 0o.001 a
70 0.6
0
.0
le 0.5
< 0-0001a J 0
F
B A C
oV
OT
L
H
S
To
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Likelihood of receiving any adjuvant systemic treatment
(odds ratio relative to GGHB)
Figure 1 Hazard ratios for death vs odds ratios for adjuvant systemic
treatment by health board. A, Ayrshire & Arran; B Borders; C, Argyll & Clyde;
F, Fife; G, Greater Glasgow; H. Highland; L, Lanarkshire; N, Grampian; S,
Lothian; T. Tayside; V, Forth Valley; Y. Dumfries & Gallway
the 2401 eligible women. records could not be located for 164 and
another 89 had been destroyed. Therefore. information was
0.016 obtained from 2148 (89%) of eligible women. However, 175 had
metastases at presentation: a further 354. most of them elderly.
were treated non-surgically. This analysis concerns the remaining
1619 women undergoing surgery for non-metastatic breast cancer.
of whom 588 had died.
The overall Kaplan-Meier estimate of5-year survival was 70.9%
(95% CI 68.6-73.1%). The effects ofclinical. treatment and service
factors on survival in univariate analyses are shown in Table 1. The
results of the adjusted Cox regression model analysis are shown in
Table 2. All ofthe clinical factors had a significant effect on survival
0°8C in both the uni- and multivariate analyses. Node positivity had a
greater effect on survival in patients with small tumours than those
with large tumours. whereas tumour size influenced prognosis prin-
074: cipally in women with node-negative disease (interaction signifi-
cant. P < 0.0001) in the multivariate analysis. After adjusting for
only clinical factors. neither the type of surgery nor use of adjuvant
016- chemotherapy. both of which influenced survival in the univanate
analysis. were of independent prognostic importance in the multi-
variate analysis. Patients who received adjuvant systemic treatment
had improved 5-year adjusted survival compared with those who
0.90C received noadjuvanttherapy. but this difference was notstatistically
significant (74.8% and 72.2% respectively: P = 0.25). 74 (71-77)
74 (71-77)
0 60c
73 (70-77)
74 (72-77)
74 (71-77)
74 (71-77)
75 (72-78)
73 (70-76)
75 (72-78)
72 (69-75)
Effect of health board
After adjusting for the effect of clinical factors. health board of
first treatment was the only service factor that independently
predicted survival in the multivariate analysis (P = 0.02).
Estimated 5-year survival ranged from 67% to 84% across the
health boards. The risk ofdeath. shown as the hazard ratio relative
to the largest health board (Greater Glasgow). was significantly
increased in three health boards (Table 3). The proportion of non-
metastatic patients who did not undergo surgery and who were
excluded from this analysis. varied significantly between health
boards (range 9.4-32.5%. P < 0.001). When these cases were
included, the effect of health board on survival no longer reached
statistical significance (P = 0.051). However. a significantly higher
Britsh Journal ofCancer (1998) 78(5), 566-571
IP-values are Wald statiscs for entry, auste for al odersignficant factors. Recause cf
the smnall populations and geo cal sianries, the Orkney, Sheoand and Western Isles
Health Boards were analysed as a single group. known as the Islands. ;P-vakies are Wald
statistics for enty. aiusted frsqgificant clinical factors only. tUe unknowns were not
rLuded in these anayses.
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Table 3 Hazard ratios of death and odds ratios for receivng aquvant
systemic treatrent by health board
Health Board No. of Adjusted hazard Percentge Adusted odds
women ratios (95% C) of women ratios (95% C)
compaed with e g for
GGHBE tremet te ent
(o I - with
GGHIP
Ayrshire & Arranb 126 1.52 (1.10-2.10) 58 0.65 (0.41-1.03)
Bordersc 22 1.46 (0.72-2.93) 50 0.38 (0.15-0.98)
Argyll &Cydeb 107 1.49 (1.06-2.10) 68 0.75 (0.45-1.24)
FifebC 91 1.55 (1.05-2.29) 41 023 (0.14-0.39)
Greater Glasgow 343 1 67 1
(GGHB)
Highlandd 72 0.97 (0.61-1.54) 93 6.71 (2.50-17.98)
Islands 25 0.64 (0.31-1.34) 100 Not applicable
Lanarkshire 135 1.20 (0.86-1.66) 74 1.34 (0.82-2.20)
Grarmpia 186 0.95 (0.69-1.31) 87 3.16 (1.90-526)
Lothiand 235 0.88 (0.65-1.19) 77 1.76 (1.16-2.66)
Tayside 148 1.33(0.94-1.87) 63 0.75 (0.48-1.19)
Forth Valley 68 1.41 (0.90-2.20) 63 0.75 (0.40-1.41)
Dumfries 61 1.11 (0.71-1.76) 74 0.96 (0.49-1.90)
& Galloway
aAqusted forsignificantdinical factors. btlealth boards in which survival was
signifiantly worse than GGHB. cPatients significantly less likely to receive
adjuvant theapy than in GGHB. dPabents sifcatly more likely to receive
aquvant therapy than in GGHB.
proportion of these women were elderly (P < 0.001). When the
analysis of all non-metastatic patients was restricted to those less
than 75 years old, health board again had a significant effect on
survival (P = 0.02).
There appears, therefore, to be an effect of health board on
survival that is not fully explained by selection for surgery and is
strongest in women aged less than 75 years. One possible explana-
tion is differences between health boards in the use of adjuvant
treatment. Table 3 shows variation in the use ofadjuvant treatment
between health boards. A multivariate logistic regression analysis,
adjusted for all ofthe clinical factors except clinical stage, showed
that health board offirsttreatment predicted independently whether
or not patients received adjuvant systemic treatment (P < 0.001).
Effect of deprivation and cae load
In the univariate analysis women from less deprived areas appeared
to have a betterprognosis. but this was not confirmed by the multi-
variate Cox model (P = 0.03 and 0.28 respectively). This is not due
to bias of selection for surgery, as deprivation still had no effect on
survival when non-surgical and non-metastatic patients were also
included (P =0.23). Forthose women whounderwent surgery, there
were, however, significant differences in ER status between depri-
vation categories (P-value forX2 ofassociation < 0.001). Women in
the most deprived group were more likely to have ER-negative
tunours than those in the intermediate or least deprived groups
(36%, 22% and 22%, respectively, were ER negative). This vari-
ability in ER status accounted, at least in part, forthe effect ofdepri-
vation in the univariate analysis ofsurgical cases.
In the univariate analysis, women operated on by surgeons with
a large case load appeared to have better 5-year survival (P =
0.03). However, age, clinical stage, node status and ER status all
differed between surgeons with differing case loads (all P-values
forX ofassociation <0.001). In the multivariate survival analysis.
the effect of case load was no longer apparent (P= 0.74).
suggesting that case mix accounts for the effect on survival in the
univariate analysis. Referral to an oncologist did not significantly
affect survival.
DISCUSSION
This study shows significant variability in the survival of women
with breast cancer that is not fully accounted for by clinical
factors. The most important finding is that. although geographical
differences in the selection of patients for surgery account for
some of this variability, the health board of first treatment has an
effect on survival. This may be explained in part by differences in
the proportion ofpatients receiving adjuvant systemic therapy. By
contrast, neither surgical case load nor socioeconomic deprivation
significantly affected survival when other factors were taken into
account. These findings are strengthened by this being a national.
population-based study that included 89% of eligible patients
diagnosed recently in a single year. across a heterogeneous but
well-defined geographical area Importantly, the current study
obtained detailed information directly from the case notes rather
than relying solely on cancer registry data.
The influence of Health Board on survival was less strong than
that ofclinical factors, but among surgical patients adjusted 5-year
survival varied from 67% to 84% between health boards.
Variations in survival have also been described between different
regions of Yorkshire (Sainsbury et al, 1995b) and between
teaching and non-teaching hospitals in the South of England
(Basnett et al, 1992). Part of the variability in survival in the
current study was due to the selection of patients for surgery.
When all non-metastatic patients, as opposed to only those treated
surgically, were included the effect of health board no longer
reached statistical significance. However. the patients treated non-
surgically were mostly elderly and at greater risk of death from
other causes. When the analysis was restricted to all non-
metastatic patients under 75 years, in whom non-cancer deaths are
less common, the effect of health board on survival was again
significant. Health board had a similareffect on survival in women
undergoing surgery when only breast cancer deaths were consid-
ered (P = 0.05; data not shown). There appears. therefore, to be an
effect of health board on survival that is greatest in women less
than 75 years old.
This remaining variation in survival may be due to differences
in the use of adjuvant systemic therapy, in most cases tamoxifen.
between the health boards. There was a trend for survival to be
worse in those health boards in which adjuvant systemic treatmient
was less widely used (Figure 1). This is a plausible explanation
given the known effect of adjuvant treatment on survival in clin-
ical trials (Early Breast Cancer Trialists' Collaborative Group.
1992). In our analysis, the effect of adjuvant systemic treatment
did not achieve statistical significance, possibly because it was not
a randomized trial, hence the use oftreatment was confounded or
driven by clinical factors. In the current analysis, the adjusted 5-
year survival for women given any adjuvant systemic treatment
was 75% (99% CI 72-78%), compared with 72% (99% CI
69-75%) in those who did not receive such treatment. This differ-
ence was not statistically significant. but is ofthe same magnitude
as the known 3.5% survival advantage ofadjuvant systemic treat-
ment at 5 years (Early Breast Cancer Trialists' Collaborative
Group, 1992). Our study, however, had only 35% power (Parmnar
and Machin. 1995) to detect a survival advantage ofthe magnitude
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reported in the overviewv. The importance of a relationship
between rates of use of adjuvant treatment and survival is
supported by the geographical variations in the treatment ofbreast
cancer in other parts ofBritain (Basnett et al. 1992: Chouillet et al.
1994: Sainsburv et al. 1995b: Richards et al. 1996). In Scotland.
there was a substantial and appropriate increase in the use of adju-
vant systemic treatment between 1987 and 1993 (Scottish Breast
Cancer Focus Group et al. 1996). the impact of which will be
apparent when survival data from the 1993 cohort of women are
mature.
Previous studies have sucyested that survival is better for
patients of surgeons seeing at least 30 women with breast cancer
each year (Sainsburv et al. 1995a) or with a perceived interest in
breast cancer. irrespective of their case load (Gillis and Hole.
1996). Our data support those of Sainsbury et al (1995a) in that
surgical caseload significantly influenced unadjusted survival.
However. this effect appeared to be explained by case mix as it
was no longer apparent after adjusting for other prognostic factors
that were better characterized by the more detailed data collection
in the current studv. We did not categorize surgeons in the same
way as Gillis and Hole (1996). who defined 'specialist' breast
cancer surgeons after taking advice according to informed opinion
and not numerically by case load. Nevertheless. taken together.
these studies suaaest that there is a 'surgeon effect' but this relates
to better overall care rather than the numbers of women operated
upon. Indeed. the Yorkshire study showed that surgeons with a
higher case load were also more likely to use chemotherapy and
hormone therapy (Sainsbur et al. 1995b).
Our findings in relation to deprivation and unadjusted survival
support data adjusted only for age in 7537 women from the West
of Scotland Cancer Registrv (Carnon et al. 1994). When we
adjusted survival for other factors. in particular ER status. the
trend for poorer survival in the more deprived women persisted.
but was no longer statistically significant. Unlike the current
studv. Carnon et al ( 1994) did not adjust survival for known prog-
nostic factors. Rather. they looked at a subgroup of 1361 women
and found no differences in pathological features between the
deprived and affluent women. Carnon et al (1994) did not.
however. report any relationship between adjusted survival and
depri'vation in this subgroup of women for whom they had
pathology data. Many other earlier studies used only registr data
and were also able to adjust for a limited number of prognostic
factors (Marshall & Funch. 1983: Karjalainen and Pukkala. 1990:
Schrijvers et al. 1995). The current large. detailed population
study verifies that deprivation influences unadjusted survival but
appears not to be a significant. independent prognostic factor for
survival. The effect of deprivation on the survival of women with
breast cancer remains unproved.
The increasing evidence that service factors related to the
deliverv of health care affect survival has important implications
for the provision of cancer services. The current study suggests
that regional differences in practice. probably related to the use of
adjuvant systemic treatment. man influence survival in women
with early breast cancer. It is clear that too many hospitals are
treating women with breast cancer and that many do not have the
multidisciplinary teams needed for optimal care (Richards et al.
1996). Currently. only half the patients with cancer in Britain are
seen by an oncologist (Richards and Parrott. 1996) and the
majority of women are not operated on by a surgeon with a special
interest in breast cancer (Gillis and Hole. 1996). It is important
that the development of specialist breast cancer services continues
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in order that all women have access to unifornlsv high standards of
care as specified by the Expert Advisonr Group on Cancer (Expert
Advisorv Group on Cancer. 1995). Richards et al (1997) recently
discussed a model for delivefinn cancer services based upon the
West Midlands model.
Taken together. the current study and earlier reports demon-
strate the importance of a specialist breast service. rather than a
large surgical case load or socioeconomic deprivation. in influ-
encin, the survival of women with breast cancer. The findingc of
Geographical variations in survival. probably related to the use of
adjuvant systemic treatment. has important implications for both
the purchasers and the providers of cancer services. Addressing
these differences in care could have a significant impact on overall
survival for women with breast cancer.
ACKNOWLEDGEMENTS
The members of the Scottish Breast Cancer Focus Group are Dr
JA Dewar (Chairman). Dr TJ Anderson. Mr DB Booth. Mr U
Chettv. Professor WAD George. Professor FJ Gilbert. Dr A Gould.
Dr AN Harnett. Dr M Hennigan. Dr G McIlwaine. Dr U Mcleod.
Miss G McPhail. Dr ATB Moir. Mis F Sandford. Mr DC Smith. Dr
CJ Twelves and Dr LG Walker. We thank Dr D Brewster. Mr R
Black. the SCTN staff and data managers. the members of the
Scottish Cancer Trials Breast Group and Dr D Hole for their
support and comments. The SCTN is funded by the Chief Scientist
Office and the Clinical Resource and Audit Group of the Scottish
Office Department of Health.
REFERENCES
Arm-itage P and Bern G 1 1994) Statistical Methods in Medical Research. 3rd edn.
Black%%ell Scientific Publications: Oxford
Basnett I. Gill MI and Tobias JS (1992 Variations in breast cancer management
between a teaching and a non-teachine district. Eur J Cancer 28A: 1945-1950
Brewster D. Crichton J and Muir C 1994- How accurate are Scottish cancer
re istration data" Br J Cancer 70: 954-959
Brewster D. Crichton J. Harvey JC and DaAson G (1997 Completeness ofcase
ascertainment in a Scottish reeional cancer registrv for the \ear 1992. Pub HIth
111: 3.39-343
Carnon AG. Ssemrnogerere A. Lamont D". Hole DJ. Mallon EA. George WD and
Gilles CR (1994) Relation between socio-economic depri\ation and
pathological prognostic factors in Aomen Aith breast cancer. BrMed J 309:
1054-1057
Carstairs V and Morris R (1991 Deprivation and Health in Scotland. Aberdeen
Universitx Press: Aberdeen
Chouillet AM. Bell C\.U and Hiscox JG (1994) Management ofbreast cancer in
Southeast England. BrMed J308: 168-171
Collett D (1994) .Vodelling Survival Data in Medical Research. Chapman & Hall:
London
Eafrl Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of
early breast cancer by hormonal. cvtotoxic. or immune therap!. Lancet 339:
1-15. 71-85
Expert Advisor\ Group on Cancer (199-5 4 Polic Framez-ork- tor Commissioning
Cancer Serivices. Department of Health: London
Gillis CR and Hole DJ (1996) Survival outcome ofcare b\ specialist surgeons in
breast cancer a study of 3786 patients in the West of Scotland. BrMed J312:
145-148
Karjalainen S and Pukkala E (1990) Social class as a prognos.tic factor in breast
cancer survival. Cancer 66: 819-82'6
Kendrick S and Clarke J (1993) The Scottish record linkaee sstem. Hlth Bull 51:
72-79
Marshall JR and Funch DP (1983 Social environment and breast cancer a cohort
analvsis of patients survival. Cancer 52: 1546-1550
M~aud~sley- G and Williams EMII (1993 Death certification by House Officers
and General Practitioners - practice and performance. I Pub Hlth Mied 15:
192-201
C) Cancer Research Campaign 1998Parmar KB and Machin D ( 1995) SurvivalAnahlsis: A Practical Approach. Wiley:
Chichester
Richards MA and Parrott JC (1996) Tertiary cancer serices in Britain:
bechmarking sntud ofacti'ity and facilities at 12 specialist centres. BrMedJ
313: 347-349
Richards MA. Wolfe CDA. Tilling K. Barton J. Bourne HM and Gregory WM
(1996) Variations in the ma nt and sunrival ofwomen under
50 years with breast cancer in the South East Thames region BrJ Cancer
73: 751-757
Richards M. Sainsbuy R and Kerr D (1997) Inequalities in breast cancer care and
outcome. BrJ Cancer76: 634-683
0Canoer Research Cmaign 1998
Breast cancersurvival in Scoland 571
Sainsbwy R. Haward B. Rider L Johnston C and Round C (I995a) Influence of
clinician workload and patterns oftreatment on survival from breast cancer.
Lancet345: 1265-1270
Sainsbrv JRC. Rider L Smith A and McAdam WFA (1995b) Does it matter where
you live? Treatment variation for breast cancer in Yorkshire. BrJ Cancer71:
1275-1278
Schrijvers CTM. Mackenbach JP. Lutz J-M. Quinn MJ and Coleman MP (1995)
Deprivation and survival from breast cancer. BrJ Cancer 72: 738-743
Scottish Breast Cancer Foecus Group. Scottish CancerTrials Breast Group. Scottish
Cancer Therapy Network ( 1996) Scottish Breast CancerAudit 1987and 1993.
Scottish Cancer Theray Network: Edinbwrgh.
Britsh Journal ofCancer (1998) 78(5), 566-571